ACM
PTGX icon

Atika Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Atika Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.55M Sell
62,100
-23,900
-28% -$2.12M 0.82% 35
2025
Q4 		$7.51M Buy
86,000
+3,000
+4% +$246K 0.79% 39
2025
Q3 		$5.51M Buy
+83,000
New +$4.72M 0.44% 54

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Atika Capital Management's PTGX Position: Q1 2026 in Review

Atika Capital Management reduced its Protagonist Therapeutics (PTGX) stake by 28% in Q1 2026, selling an estimated $2.12M and leaving 62,100 shares worth $6.55M. The position accounts for 0.82% of the portfolio, ranked #35.

Atika Capital Management first reported a position in PTGX in Q3 2025 and has held it in 3 quarters since. The position peaked at $7.51M in Q4 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Atika Capital Management held 62,100 shares of Protagonist Therapeutics worth $6.55M as of Q1 2026.
  • Atika Capital Management sold 23,900 Protagonist Therapeutics shares in Q1 2026, an estimated $2.12M.
  • Protagonist Therapeutics made up 0.82% of Atika Capital Management's portfolio in Q1 2026, its #35 holding.
  • Atika Capital Management first reported a position in Protagonist Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Atika Capital Management's Protagonist Therapeutics position peaked at $7.51M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Atika Capital Management's 13F filing for Q1 2026, filed 14 May 2026.